Media

Australia-led international study shows ways to reduce organ failure risk in COVID-19 patients

 

By Yumi Oba
Published: Mon 19 Dec 2022

The Australasian COVID-19 Trial (ASCOT) was conducted with more than 1,500 participants in 32 hospitals across Australia, New Zealand, India and Nepal.

East Mojo - Intermediate dose of blood thinners works well for Covid patients than high or low dose: Study

Posted: Wed 14 Dec 2022

According to officials, patients in hospital with COVID-19 are at increased risk of blood clots (or thromboses), which in turn may contribute to development of organ failure.

An intermediate level of anticoagulation (blood thinning) had an 86 per cent probability of being more helpful than low or high dose anticoagulation in Covid patients, according to a new study.

El Mirage News - Research Recommends Anticoagulant for COVID Patients

Posted: Sun 11 Dec 2022

In an international study, the ASCOT team conducted a randomised clinical trial to test different levels of anticoagulation (or blood thinning) in more than 1,500 patients in Australia, New Zealand, India and Nepal.

They found that an intermediate level of anticoagulation had an 86% probability of being better than low dose anticoagulation. A higher therapeutic dose did not show any benefit.

TodayUKNews - Study reveals recommended anticoagulant therapy for COVID patients

Posted: Sun 11 Dec 2022

The AustralaSian COVID-19 Trial (ASCOT) has pinpointed the most efficient level of blood thinning treatment needed for patients hospitalized with COVID-19, in a study published in the New England Journal of Medicine Evidence and presented at the American Society for Hematology conference today.

Scienmag - Study reveals recommended anticoagulant therapy for COVID patients

Posted: Sat 10 Dec 2022

The COVID-19 global pandemic remains a major public health challenge. ASCOT researchers aim to discover which treatments are most effective in patients hospitalised with COVID-19.

Patients in hospital with COVID-19 are at increased risk of blood clots (or thromboses), which in turn may contribute to development of organ failure. Almost all these patients will receive some degree of blood thinning medication.

The National Tribune - Study reveals recommended anti-clotting therapy for COVID patients

Posted: Sun 11 Dec 2022

The AustralaSian COVID-19 Trial (ASCOT) has pinpointed the most efficient level of anti-clotting treatment needed for patients hospitalised with COVID-19. Patients in hospital with COVID-19 are at increased risk of blood clots (or thromboses), which in turn may contribute to the development of organ failure. Almost all these patients will receive some degree of anti-clotting medication.

In an international study, the ASCOT team, including Prof Bala Venkatesh and Prof Vivek Jha from The George Institute, conducted a randomised clinical trial to test the different levels of anti-clotting medication in more than 1,500 patients in Australia, New Zealand, India and Nepal.

New Medical Life Sciences - ASCOT trial pinpoints most efficient level of blood thinning treatment for hospitalized COVID-19 patients

By Emily Henderson
Posted: Mon 12 Dec 2022

The AustralaSian COVID-19 Trial (ASCOT) has pinpointed the most efficient level of blood thinning treatment needed for patients hospitalized with COVID-19, in a study published in the New England Journal of Medicine Evidence and presented at the American Society for Hematology conference today.

The COVID-19 global pandemic remains a major public health challenge. ASCOT researchers aim to discover which treatments are most effective in patients hospitalized with COVID-19.

eMed News - Study reveals recommended anticoagulant therapy for COVID patients

By Dr Lekha
Posted: Mon 12 Dec 2022

The AustralaSian COVID-19 Trial (ASCOT) has pinpointed ‘anticoagulant therapy’ as the most efficient level of blood thinning treatment needed for patients hospitalized with COVID-19, in a study published in the New England Journal of Medicine Evidence and presented at the American Society for Hematology conference today.

The Examiner - Aust trial treats COVID-19 blood clots

By Farid Farid
Posted: Sun 11 Dec 2022

An Australasian clinical trial has shed light on the most efficient level of blood thinning treatment needed for patients hospitalised with COVID-19.

The Print - Intermediate dose of blood thinners works well for Covid patients than high or low dose: Study

By PTI
Posted: Tue 13 Dec 2022

An intermediate level of anticoagulation (blood thinning) had an 86 per cent probability of being more helpful than low or high dose anticoagulation in Covid patients, according to a new study.

The Indian Express - An intermediate dose of blood thinners saves Covid patients, says new study

By Anuradha Mascarenhas
Posted: Wed 14 Dec 2022

"Our findings show that an intermediate level of anti-coagulation had an 86 per cent probability of working better than low-dose anti-coagulation. A higher therapeutic dose did not show any benefit," says Dr Vivekanand Jha, Executive Director of the George Institute for Global Health.

The Hindu Business Line - Intermediate dose of blood thinners works well for Covid patients than high or low dose: Study 

By PTI
Posted: Tue 13 Dec 2022

The study was based on randomised clinical trial to test different levels of anticoagulation in more than 1,500 patients in India, Australia, New Zealand and Nepal.

Coronacast - How will fancy new antivirals help fight COVID?

On Coronacast with Norman Swan
Posted: Mon 7 Feb 2022, 1:01am

When it comes to ways to fight COVID-19, vaccines have been the main tool we've used so far during the pandemic.
But new antivirals are being produced for use including in Australia which has recently provisionally approved two different drugs.
They promise to help stop at-risk people ending up in hospital and dying.
So what are the drugs, how do they work and will they usher in a new way of handling the pandemic?

GUEST:
Professor Josh Davis, Infectious Diseases, Uni Newcastle, past president of the Australasian Society for Infectious Diseases and member of the National COVID-19 Clinical Evidence Taskforce

The Australian - Top doctors predict Covid-19 drugs could ease pressure on hospitals

By Natasha Robinson
Posted: Tue 09 Nov 2021

"I think it’s a great advance and what’s attractive about these oral antiviral agents is that they’re much simpler to use and distribute than the intravenous therapies or other monoclonal antibodies,” Professor Tong said. “Vaccines will still be the first line of defence, and then the patients who get through that initial net will have these back-up options of oral antivirals and the monoclonal antibody treatments.”

“It will be really significant in helping to manage the resource of hospital beds and avoiding hospital admission, and it will help prevent the Australian healthcare system from being overwhelmed,” Professor Davis said.

Newcastle Herald - What drugs treat COVID-19? The eight approved drugs include dexamethasone, Remdesivir, budesonide and monoclonal antibodies

By Damon Cronshaw
Posted: Sun 12 Sep 2021, 4:21pm

Eight drugs have been proven to reduce COVID-19-related disease severity and mortality in large randomised controlled trials, University of Newcastle Conjoint Professor Josh Davis says.

Twitter - Reflections working on one of the COVID wards in Melbourne

ABC News - Melbourne COVID ward doctor warns of 'big wave' amid increase in young, unvaccinated patients

By Matilda Marozzi
Posted: Mon 13 Sep 2021, 11:58am

Key Points:

  • Hospital staff are working "incredibly hard" to treat COVID patients on the ward and in ICU, Steven Tong says.
  • Referrals to the hospital are "rapidly picking up pace" and Dr Tong expects it to get even busier than last year.
  • Vaccination is the key to slowing down rates of infection and hospitalisation.

ABC Radio Interview - How far have treatments come?


Duration: 2min 53sec
Broadcast: Fri 10 Sep 2021, 7:00am

Until recently there've been limited therapeutic options for those who get COVID, but that is starting to change.

Featured:
Audrey, COVID survivor
Professor Joshua Davis, chair, National COVID-19 Clinical Evidence Taskforce
Steven Tong, infectious diseases physician, Royal Melbourne Hospital and Doherty Institute